Together with the study of azacitidine + sorafenib, these 2 studies show that very high rates of response can be achieved with lower-intensity FLT3 inhibitor doublets in newly diagnosed FLT3-mutated AML, although survival remains modest with these approaches. This evidence concerns the gene FLT3 and acute myeloid leukemia.